Pseudomonas aeruginosa: Recent Advances in Vaccine Development
Matthew Killough1, Aoife Maria Rodgers2, Rebecca Jo Ingram1
1Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast BT7 1NN, UK.
Abstract:
Pseudomonas aeruginosa is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, P. aeruginosa causes a range of complicated acute and chronic infections in immunocompromised individuals. Of particular importance are burn wound infections, ventilator-associated pneumonia, and chronic infections in people with cystic fibrosis. Antibiotic resistance has rendered many of these infections challenging to treat and novel therapeutic strategies are limited. Multiple clinical studies using well-characterised virulence factors as vaccine antigens over the last 50 years have fallen short, resulting in no effective vaccination being available for clinical use. Nonetheless, progress has been made in preclinical research, namely, in the realms of antigen discovery, adjuvant use, and novel delivery systems. Herein, we briefly review the scope of P. aeruginosa clinical infections and its major important virulence factors.
Insights
Pseudomonas aeruginosa infections are difficult to treat due to antibiotic resistance and limited vaccines. Research is advancing in antigen discovery and delivery systems for potential new Pseudomonas aeruginosa vaccines.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Vaccinology
Background:
- * *Pseudomonas aeruginosa* is a significant opportunistic pathogen causing severe acute and chronic infections in immunocompromised individuals.
- * Common infections include burn wounds, ventilator-associated pneumonia, and cystic fibrosis complications.
- * Antibiotic resistance and lack of effective vaccines present major therapeutic challenges.
Purpose of the Study:
- * To review the clinical scope of *Pseudomonas aeruginosa* infections.
- * To highlight key virulence factors of *Pseudomonas aeruginosa*.
- * To discuss the limitations and progress in developing *Pseudomonas aeruginosa* vaccines.
Main Methods:
- * Literature review of clinical studies on *Pseudomonas aeruginosa* infections.
- * Analysis of virulence factors and their role in pathogenesis.
- * Examination of historical and current vaccine development research.
Main Results:
- * *Pseudomonas aeruginosa* infections are diverse and challenging due to its adaptability and virulence factors.
- * Decades of vaccine development using virulence factors have not yielded clinical success.
- * Preclinical research shows promise in antigen discovery, adjuvant use, and novel delivery systems.
Conclusions:
- * *Pseudomonas aeruginosa* remains a critical threat, necessitating novel therapeutic approaches.
- * Despite past failures, ongoing preclinical advancements offer hope for future *Pseudomonas aeruginosa* vaccines.
- * Understanding virulence factors is crucial for developing effective prevention and treatment strategies.
More Related Videos
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Gene Regulation in Microbial Communities: Quorum Sensing
01:29Microorganisms in Medicine and Therapeutics